RTP Mobile Logo
Lung Cancer Update, Issue 1, 2014
Released June 2014

Featuring interviews with Drs David E Gerber, Robert C Doebele, David R Gandara and Geoffrey R Oxnard. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Lung cancer is the leading cause of cancer mortality in the United States for both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Historically, progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes, but the discovery of various mutations and biomarkers has led to the proliferation of novel targeted agents for lung cancer that have in turn led to improvements in disease-free and overall survival in select patient populations. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical and radiation oncologists with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.

    LEARNING OBJECTIVES

    • Identify distinct subtypes of adenocarcinoma of the lung — including those with EGFR mutations, EML4-ALK gene fusions, ROS1 gene rearrangement and other recently identified driver mutations — and the approved and investigational treatment options for patients with these mutations.
    • Formulate a rational approach for molecular testing of tumors to identify potential protocol and off-protocol treatment options for patients.
    • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors, and identify investigational therapeutic opportunities to circumvent this process.
    • Develop an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced non-small cell lung cancer (NSCLC).
    • Recall the scientific rationale for ongoing investigation of novel agents or immunotherapeutic approaches in lung cancer, and counsel appropriately selected patients about study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr GerberAdvisory Committee: Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology; Contracted Research: ArQule Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Peregrine Pharmaceuticals Inc. Dr DoebeleAdvisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Pfizer Inc; Contracted Research: Mirati Therapeutics. Dr GandaraAdvisory Committee: Synta Pharmaceuticals Corp; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Response Genetics Inc, Sanofi, Synta Pharmaceuticals Corp; Contracted Research: Abbott Laboratories, Bristol-Myers Squibb Company, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr OxnardAdvisory Committee: Aveo Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Honoraria: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This activity is supported by educational grants from Astellas, Biodesix Inc, Celgene Corporation, Genentech BioOncology, Lilly and Novartis Pharmaceuticals Corporation.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2014
    Expiration date: June 2015

Acknowledge and close

Listen to audio:
Lung Cancer Update, Issue 1, 2014
Released June 2014

Featuring interviews with Drs David E Gerber, Robert C Doebele, David R Gandara and Geoffrey R Oxnard. (Text and Audio Content)

Read print: